Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2026 05:08 ET | Source: Zelluna ASA

Zelluna ASA: Disclosure of large shareholding

Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 18 June 2026 regarding the total allocation of 3,143,958 new shares in the Company in a private placement...
June 17, 2026 18:28 ET | Source: Zelluna ASA

Zelluna ASA – Mandatory notification of trade – Subscription and share lending in Private Placement

Oslo, 18 June 2027: Reference is made to the stock exchange announcement published by Zelluna ASA (the "Company") on 17 June 2026 regarding completion of a placement of 3 143 958 new shares at a...
June 17, 2026 18:21 ET | Source: Zelluna ASA

Zelluna ASA: Private Placement and Retail Offering successfully placed

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION...
June 17, 2026 10:47 ET | Source: Zelluna ASA

Zelluna ASA: Contemplated Private Placement and Retail Offering to Strengthen its Position Ahead of Initial Clinical Data

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN...
May 07, 2026 01:00 ET | Source: Zelluna ASA

Zelluna ASA: First Quarter 2026 results

Oslo, 7 May 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents...
May 07, 2026 01:00 ET | Source: Zelluna ASA

Zelluna ASA: Første kvartal 2026

Oslo, 7. mai 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene "off-the-shelf" T-cellereseptor-baserte NK-celler (TCR-NK) for behandling av kreft, presenterer i dag resultatene for første...
May 06, 2026 17:18 ET | Source: Zelluna ASA

Zelluna ASA activates first clinical site for ZIMA-101, marking entry into clinical execution

Oslo, 6 May 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces...
May 06, 2026 17:18 ET | Source: Zelluna ASA

Zelluna ASA aktiverer det første kliniske senteret for ZIMA-101studien, og markerer dermed oppstart av klinisk gjennomføring

Oslo, 6. mai 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene "off-the-shelf" T-cellereseptor-baserte NK-celler (TCR-NK) for behandling av solide kreftformer, kunngjør i dag at det første...
May 04, 2026 11:58 ET | Source: Zelluna ASA

Zelluna ASA: Invitation to First Quarter 2026 results webcast Presentation (corrected time)

Oslo, Norway, 4 May 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, invites to a...
May 04, 2026 09:19 ET | Source: Zelluna ASA

Zelluna ASA: Invitation to First Quarter 2026 results webcast Presentation

Oslo, Norway, 4 May 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, invites to a...